{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        }
      ],
      "caveat": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, showing the effect is IFN-dependent."
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing increases, broadening the peptide repertoire on MHC-I and improving tumor visibility to T cells.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        },
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors; PD-L1 upregulation may vary by tumor type."
    },
    {
      "claim_id": "C04",
      "claim": "Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mouse models.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.",
          "line_ref": "L19"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, and tumor-type heterogeneity limits generalization."
    },
    {
      "claim_id": "C05",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic cancer patients receiving ICI treatment.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Human vaccinated subgroup: 43 patients.",
          "line_ref": "L22"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing varied across patients."
    }
  ]
}